Shots:

• The P-III study evaluates the efficacy and safety of patients who received HD201 (Tuznue) vs Herceptin for 1yr. and completed a median follow-up of 31mos.
• The study met its 1EPs i.e. tpCR rates (45% vs 48.7%), and showed equivalent efficacy and comparable safety profile. The 2EPs including bpCR, overall response, and response based on mammography, ultrasonography, or clinical tumor evaluations, also supported the efficacy of Tuznue
• The company is currently evaluating 3yrs. EFS and OS result in an ongoing study. The preliminary results of this final analysis indicate highly comparable 3yrs. EFS and OS rates for HD201 and Herceptin

Ref: Businesswire | Image: Prestige Biopharma